Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy
Ipilimumab, monoclonal antibody against cytotoxic T-lymphocyte antigen-4 and, radiotherapy are commonly used to treat unresectable and metastatic melanoma. As a result of upregulation of immune system with ipilimumab, many immune-related adverse effects, such as dermatitis, colitis, hepatitis, and hypophysitis, have been previously reported in literature. Typically, these effects are treated with high-dose steroids and mostly heal up. Here, we report a case who was receiving radiotherapy due to metastatic malignant melanoma with atypical generalized rash, which was enlarged with concurrent ipilimumab treatment.
Source: Journal of Oncology Pharmacy Practice - Category: Cancer & Oncology Authors: Eryılmaz, M. K., Mutlu, H., Salim, D. K., Musri, F. Y., Tural, D., Bassorgun, I., Coskun, H. S. Tags: Case Reports Source Type: research
More News: Cancer & Oncology | Dermatitis | Dermatology | Hepatitis | Melanoma | Skin Cancer | Toxicology | Yervoy